- How does processing a prescription for a drug with a complex REMS program, such as one requiring ETASU, typically alter the standard pharmacy workflow?
Answer: It adds verification steps that must be completed before the final medication check.
REMS programs add extra steps to the dispensing process. These often include verifying prescriber certification, checking a REMS database for patient authorization, or ensuring lab work is complete. These verification steps must be performed before the pharmacist's final check and will lengthen, not shorten, the overall processing time.
- For certain high-risk medications, a REMS program may require patient enrollment. What is the primary reason for this requirement?
Answer: To ensure the patient has received education on the risks and agrees to monitoring.
Patient enrollment is a mechanism to confirm that the patient has been counseled on the significant risks of the medication and formally agrees to comply with any required safety measures, such as periodic lab tests or pregnancy tests.
- What is the primary purpose of a Risk Evaluation and Mitigation Strategy (REMS) program as mandated by the FDA?
Answer: To ensure the benefits of a medication outweigh its risks.
The primary goal of an FDA-required REMS program is to ensure that a medication's known or potential serious risks do not outweigh its benefits for the patient. The other options describe different programs or concepts. Tracking the supply chain is covered by the DSCSA. Reporting adverse events is done through programs like MedWatch. Establishing cost is a function of the manufacturer and market, not a REMS program.
- A REMS program can include several components. Which of the following is a potential core component of a comprehensive REMS program?
Answer: Elements to Assure Safe Use (ETASU)
Elements to Assure Safe Use (ETASU) are a key part of more restrictive REMS programs. They can include requirements like prescriber certification or patient monitoring. The other options are related to marketing or cost-management and are not components of a REMS safety program.
- While entering a new prescription, a pharmacy technician receives a computer alert stating "REMS DRUG - VERIFY REQUIREMENTS." What is the most appropriate next step for the technician?
Answer: Stop and follow the pharmacy's specific procedures for handling REMS medications.
A computer alert for a REMS drug is a critical safety warning. The technician must stop the normal workflow and follow the pharmacy's specific policy and procedures for that REMS drug, which may involve checking a website, verifying enrollment, or obtaining an authorization number before proceeding.
- What is a potential consequence for a pharmacy that repeatedly fails to comply with the requirements of a mandatory REMS program?
Answer: The pharmacy may be prohibited from dispensing the REMS medication.
If a pharmacy does not adhere to the required safety protocols of a REMS program, the manufacturer or the FDA can take action, which may include revoking the pharmacy's certification or ability to obtain and dispense that specific medication. DEA registration is related to controlled substances, not directly to REMS compliance.
- Who is responsible for developing and proposing a REMS program for a specific medication?
Answer: The medication's manufacturer
The manufacturer of the medication is responsible for developing the REMS program. The FDA then reviews and approves the program before the drug can be marketed. The DEA is involved with controlled substances, and State Boards of Pharmacy regulate the practice of pharmacy at the state level.
- A REMS program includes a "Communication Plan." What is the main purpose of this component?
Answer: To send letters and educational materials about the drug's risks to healthcare providers.
A Communication Plan within a REMS program is designed to educate healthcare providers (including pharmacists, technicians, and prescribers) about the risks associated with the medication and the specific requirements of the REMS program to ensure safe use.
- According to the iPLEDGE REMS program, after receiving an authorization, a pharmacy has a limited time frame to dispense isotretinoin for a female patient of childbearing potential. This "dispensing window" is typically based on the:
Answer: date of the patient's negative pregnancy test.
The iPLEDGE dispensing window (typically 7 days) for female patients of childbearing potential starts from the date the specimen was collected for the qualifying negative pregnancy test. The pharmacy must dispense the medication within this window, or a new authorization process must be started.
- A patient asks a technician why they have to sign a special form and get blood work for their medication, but not for their antibiotic. The technician should recognize this is likely due to:
Answer: a Risk Evaluation and Mitigation Strategy (REMS) program.
Specific requirements such as patient consent forms, regular lab monitoring (blood work), and certified prescribers or pharmacies are hallmarks of a REMS program with ETASU. DSCSA deals with product tracing. PDMPs track controlled substances. Standard brand-name drugs do not have these requirements unless they are under a REMS.
- When processing a prescription for a medication with a REMS program, a pharmacy technician's key responsibility might include:
Answer: verifying the prescriber is certified under the specific REMS program.
A crucial step in the REMS workflow that a technician can perform is verifying that the prescriber and/or pharmacy is certified as required by the program, often through a website or call center. The other actions (diagnosing, recommending OTCs, changing doses) are outside the technician's scope of practice and must be performed by a pharmacist or prescriber.
- Before dispensing a medication subject to a REMS with Elements to Assure Safe Use (ETASU), what must a pharmacy typically obtain and document?
Answer: An authorization number from the REMS program administrator
For many complex REMS drugs (e.g., isotretinoin, thalidomide), the pharmacy must access the REMS system to verify all requirements are met. The system then provides a specific authorization or confirmation number that permits the pharmacy to dispense the drug and must be documented.
- The iPLEDGE REMS program is required for dispensing isotretinoin. A key requirement for this program that the pharmacy must verify before dispensing to a female patient of childbearing potential is:
Answer: a negative laboratory-based pregnancy test within the last 7 days.
The iPLEDGE program has a strict requirement for a negative pregnancy test from a CLIA-certified lab within 7 days before dispensing for female patients of childbearing potential. This is a core safety feature to prevent teratogenicity. While insurance pre-authorization may be needed, it is not a REMS requirement.
- A prescription for clozapine is presented at the pharmacy. As part of the Clozapine REMS, what must the pharmacy verify before dispensing?
Answer: The patient's most recent Absolute Neutrophil Count (ANC).
The Clozapine REMS program exists to manage the risk of severe neutropenia, a potentially fatal blood condition. Therefore, the pharmacy must verify that the patient has a current Absolute Neutrophil Count (ANC) that is within the acceptable range before each dispensing.
- The Transmucosal Immediate-Release Fentanyl (TIRF) REMS program is designed to mitigate the risk of misuse, abuse, and overdose. A key element of this program is:
Answer: limiting its use to patients who are opioid-tolerant.
A core safety requirement of the TIRF REMS is to ensure these potent immediate-release fentanyl products are only prescribed for and used by patients who are already tolerant to round-the-clock opioid therapy. Use in an opioid-naïve patient could be fatal due to respiratory depression.
- Many REMS programs require that a Medication Guide be dispensed with the prescription. When must the technician ensure a Medication Guide is given to the patient?
Answer: With every dispensing of the medication.
When a Medication Guide is a required part of a REMS program, federal law mandates that it be provided to the patient with every dispensing of the medication, including refills, to reinforce the safety information.
- Not all REMS programs are the same. What is the simplest and most common type of REMS requirement?
Answer: Dispensing the medication with a Medication Guide.
The most basic level of a REMS program is the requirement to provide a Medication Guide to the patient with each dispensing. More complex programs add on Elements to Assure Safe Use (ETASU), such as patient enrollment, prescriber certification, or specific clinical monitoring.
- A patient has a prescription for a buprenorphine product for opioid use disorder, which is subject to a REMS program. What must the pharmacy ensure before dispensing a refill?
Answer: All REMS requirements are met for each individual fill, not just the first one.
Compliance with a REMS program is required for every dispensing, not just the initial fill. The pharmacy must ensure that any required verifications (e.g., prescriber is certified, counseling is offered) are completed for each refill to ensure continued safe use.
- Under the Clozapine REMS program, a patient's prescription can be dispensed if their most recent Absolute Neutrophil Count (ANC) is within the acceptable range. Dispensing is contraindicated if the patient's ANC indicates:
Answer: severe neutropenia.
The entire purpose of the Clozapine REMS is to monitor for and prevent clozapine-induced agranulocytosis, which is characterized by severe neutropenia (a dangerously low level of neutrophils). If a patient's ANC falls below the acceptable threshold, dispensing is prohibited to protect the patient.
- Which of the following is an example of an "Element to Assure Safe Use" (ETASU) that might be required by a REMS program?
Answer: The pharmacy must be certified to dispense the medication.
Pharmacy certification is a common ETASU, ensuring that the pharmacy understands and can follow the specific dispensing procedures. Dispensing a large initial supply (B) is contrary to the safety goals of most REMS. Storage requirements (C) are typically based on DEA scheduling, not REMS. Samples (D) are a marketing practice.
